Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis.
- Author:
In Chang CHO
1
;
Han Soo CHUNG
;
Kang Su CHO
;
Jeong Eun KIM
;
Jae Young JOUNG
;
Ho Kyung SEO
;
Jinsoo CHUNG
;
Weon Seo PARK
;
Eun Kyung HONG
;
Kang Hyun LEE
Author Information
1. Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. uroonco@ncc.re.kr
- Publication Type:Original Article
- Keywords:
Prostatic neoplasms;
Proto-oncogene proteins;
B-cell leukemia/lymphoma 2;
Recurrence;
Prostatectomy
- MeSH:
Adenocarcinoma;
Humans;
Neoadjuvant Therapy;
Neoplasm Grading;
Proportional Hazards Models;
Prostate;
Prostate-Specific Antigen;
Prostatectomy;
Prostatic Neoplasms;
Proto-Oncogene Proteins;
Recurrence;
Seminal Vesicles
- From:Cancer Research and Treatment
2010;42(3):157-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR). MATERIALS AND METHODS: This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model. RESULTS: Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (> or =8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012). CONCLUSION: Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.
